Currently, immune checkpoint inhibitors (targeting PD-1, PD-L1, and CTLA-4) are the only validated targeted therapy for UPS, reflecting the frequent mutational events that activate immune response pathways. This evidence concerns the gene CD274 and undifferentiated pleomorphic sarcoma.